Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease

被引:29
|
作者
Nicoletti, Alessandra [1 ]
Mostile, Giovanni [1 ]
Nicoletti, Giuseppe [2 ]
Arabia, Gennarina [3 ]
Iliceto, Giovanni [4 ]
Lamberti, Paolo [4 ]
Marconi, Roberto [5 ]
Morgante, Letterio [6 ]
Barone, Paolo [7 ]
Quattrone, Aldo [3 ]
Zappia, Mario [1 ]
机构
[1] Univ Catania, Sect Neurosci, Dept GF Ingrassia, Via Santa Sofia 78, I-95123 Catania, Italy
[2] CNR, Ist Bioimmagini & Fisiol Mol, Catanzaro, Italy
[3] Magna Graecia Univ Catanzaro, Neurol Clin, Catanzaro, Italy
[4] Univ Bari, Dipartimento Sci Med Base Neurosci & Organi Senso, Bari, Italy
[5] Osped Misericordia, Div Neurol, Grosseto, Italy
[6] Univ Messina, Dipartimento Neurosci, Messina, Italy
[7] Univ Salerno, Dipartimento Med & Chirurg, I-84100 Salerno, Italy
关键词
Parkinson's disease; Dyskinesia; Clinical phenotype; Tremor-dominant; Akinetic-rigid; ONSET;
D O I
10.1007/s00415-016-8075-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It is unclear whether patients with different clinical phenotypes of Parkinson's disease (PD) differ in their risk of developing levodopa-induced dyskinesia. We evaluated the possible association between clinical phenotypes and risk of levodopa-induced dyskinesia in PD patients using a case-control design. The FRAGAMP study is a large Italian multicenter study. Patients affected by PD diagnosed according to the Gelb's criteria were enrolled and underwent a face-to-face interview. Clinical scales were used to evaluate motor and cognitive impairment. Presence of dyskinesia was assessed by the item 32 of the UPDRS section IV. On the basis of the most prominent motor symptoms at onset PD, patients were classified as tremor-dominant, akinetic-rigid, or mixed type. 485 PD patients (292 men; mean age 65.6 +/- A 9.8) were enrolled in the study of whom 128 (26.4 %) presented levodopa-induced dyskinesia. Of the 485 patients, 311 (64.1 %) were classified as tremor-dominant, 104 (21.4 %) as Akinetic-Rigid and 70 (14.4 %) as mixed type. Multivariate logistic regression analysis showed a significant negative association between tremor-dominant phenotype and levodopa-induced dyskinesia (adjusted OR 0.48; 95 % CI 0.23-1.00; p value 0.05). When analysis was stratified by age at onset a stronger negative association was found among the late onset (> 50 years) PD patients (OR 0.28; 95 % CI 0.11-0.70; p value 0.007) while no association was found among patients with an early onset. Our findings support the hypothesis that the occurrence of resting tremor as an initial manifestation of PD may predict a lower probability of developing levodopa-induced dyskinesia.
引用
收藏
页码:888 / 894
页数:7
相关论文
共 50 条
  • [41] A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson’s Disease
    Hagen Blankenburg
    Marika Falla
    Christine Schwienbacher
    Giovanni Fabbrini
    Alfredo Berardelli
    Peter P. Pramstaller
    Francisco S. Domingues
    [J]. Neuroinformatics, 2017, 15 : 297 - 300
  • [42] Levodopa-induced dyskinesia in Parkinson's disease: Epidemiology, etiology, and treatment
    Zesiewicz, Theresa A.
    Sullivan, Kelly L.
    Hauser, Robert A.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2007, 7 (04) : 302 - 310
  • [43] Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease
    Hashim, H. Z.
    Norlinah, M. I.
    Nafisah, W. Y.
    Tan, H. J.
    Raymond, A. A.
    Tamil, A. M.
    [J]. INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2014, 124 (03) : 187 - 191
  • [44] Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort
    Eusebi, Paolo
    Romoli, Michele
    Paoletti, Federico Paolini
    Tambasco, Nicola
    Calabresi, Paolo
    Parnetti, Lucilla
    [J]. NPJ PARKINSONS DISEASE, 2018, 4
  • [45] Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
    Paolo Eusebi
    Michele Romoli
    Federico Paolini Paoletti
    Nicola Tambasco
    Paolo Calabresi
    Lucilla Parnetti
    [J]. npj Parkinson's Disease, 4
  • [46] Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia
    Sosero, Yuri L.
    Bandres-Ciga, Sara
    Ferwerda, Bart
    Tocino, Maria T. P.
    Belloso, Diaz R.
    Gomez-Garre, Pilar
    Faouzi, Johann
    Taba, Pille
    Pavelka, Lukas
    Marques, Taina M.
    Gomes, Clarissa P. C.
    Kolodkin, Alexey
    May, Patrick
    Milanowski, Lukasz M.
    Wszolek, Zbigniew K.
    Uitti, Ryan J.
    Heutink, Peter
    van Hilten, Jacobus J.
    Simon, David K.
    Eberly, Shirley
    Alvarez, Ignacio
    Krohn, Lynne
    Yu, Eric
    Freeman, Kathryn
    Rudakou, Uladzislau
    Ruskey, Jennifer A.
    Asayesh, Farnaz
    Menendez-Gonzalez, Manuel
    Pastor, Pau
    Ross, Owen A.
    Krueger, Rejko
    Corvol, Jean-Christophe
    Koks, Sulev
    Mir, Pablo
    De Bie, Rob M. A.
    Iwaki, Hirotaka
    Gan-Or, Ziv
    [J]. MOVEMENT DISORDERS, 2024,
  • [47] Assessment of Parkinson’s disease levodopa-induced dyskinesia: a qualitative research study
    William R. Lenderking
    Sally Mannix
    Jennifer Petrillo
    Christopher Kenney
    Amanda Landrian
    Anette-Eleonore Schrag
    [J]. Quality of Life Research, 2015, 24 : 1899 - 1910
  • [48] Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study
    Sieradzan, KA
    Fox, SH
    Hill, M
    Dick, JPR
    Crossman, AR
    Brotchie, JM
    [J]. NEUROLOGY, 2001, 57 (11) : 2108 - 2111
  • [49] Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia
    Su, Dongning
    Gan, Yawen
    Zhang, Zhe
    Cui, Yusha
    Zhang, Zhijin
    Liu, Zhu
    Wang, Zhan
    Zhou, Junhong
    Sossi, Vesna
    Stoessl, A. Jon
    Wu, Tao
    Jing, Jing
    Feng, Tao
    [J]. MOVEMENT DISORDERS, 2023, 38 (04) : 616 - 625
  • [50] Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
    Schaeffer, Eva
    Pilotto, Andrea
    Berg, Daniela
    [J]. CNS DRUGS, 2014, 28 (12) : 1155 - 1184